Neuphoria Therapeutics Inc.
NEUP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NEUP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NEUP
Neuphoria Therapeutics Inc. (NEUP) is a clinical-stage biopharmaceutical company focused on developing central nervous system (CNS) therapies, with its lead candidate BNC210 in clinical development and no approved products or revenue to date.
Key risk: No approved products or revenue
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 2 pipeline candidates for Neuphoria Therapeutics Inc..
Similar companies
Neuphoria Therapeutics Inc. (NEUP) is a clinical-stage biopharmaceutical company focused on developing central nervous system (CNS) therapies, with its lead candidate BNC210 in clinical development and no approved products or revenue to date.
- Lead CNS product candidate BNC210 is in clinical development, with additional wholly owned programs in preclinical or discovery stage [sec · filed 2023-10-18].
- As of March 31, 2026, the company had cash and equivalents of $19.4 million and shareholders' equity of $26.0 million [sec].
- Operations have been financed primarily by aggregate net proceeds of $211.0 million from various sources as of March 31, 2026 [sec_mda · as of 2026-05-15].
- The company has incurred net losses historically, with a net income of -$0.5 million for the period ended March 31, 2026 [sec].
- BNC210 has been observed in clinical trials to have a fast onset of action and clinical activity without the limiting side effects seen with current standard of care [sec_mda · as of 2026-05-15].
What works
- BNC210 targets indications where FDA-approved therapies have not been updated in nearly two decades, offering a potential novel treatment option [sec_mda · as of 2026-05-15].
- BNC210 has shown a fast onset of action and clinical activity without the limiting side effects (abuse liability, addiction potential, withdrawal symptoms) of existing treatments [sec_mda · as of 2026-05-15].
- The company has raised substantial capital ($211.0 million aggregate net proceeds) to fund operations and development [sec_mda · as of 2026-05-15].
What to weigh
- The company has no approved products and has never generated revenue from product sales; it expects to continue incurring losses for the foreseeable future [sec · filed 2023-10-18].
- The approach to discovery and development of product candidates is unproven, and there is no guarantee of developing any products of commercial value [sec · filed 2023-10-18].
- The company will require substantial additional financing to achieve its goals, and failure to obtain such financing could delay or eliminate development programs [sec · filed 2023-10-18].
- Clinical trial results may fail to replicate earlier positive findings, which could prevent successful development or regulatory approval [sec_mda · as of 2026-02-17].
From the filings
Quoted directly from source documents.
Lead candidate BNC210 is in clinical development; other programs are preclinical.
“Our lead CNS product candidate, BNC210, is in clinical development, and our additional wholly owned CNS development programs remain in the preclinical or discovery stage.”
SEC filings · October 18, 2023
BNC210 has shown fast onset and fewer side effects than current standard of care.
“BNC210 has been observed in our clinical trials to have a fast onset of action and clinical activity without the limiting side effects seen with the current standard of care.”
SEC MD&A · May 15, 2026
The company has never generated revenue from product sales and expects continued losses.
“Our product candidates will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from such product sales, if any. We expect to continue to incur losses for the foreseeable future”
SEC filings · October 18, 2023
Risks & what to watch (4)›
Key risks
- No approved products or revenue — The company has no approved products and has never generated revenue from product sales; it expects to continue incurring losses [sec · filed 2023-10-18].
- Substantial additional financing needed — The company will require substantial additional financing to achieve its goals; failure to obtain it could delay or terminate development programs [sec · filed 2023-10-18].
- Clinical trial failure risk — Clinical trials may fail to replicate earlier positive results, preventing successful development or regulatory approval [sec_mda · as of 2026-02-17].
- Unproven development approach — The company's approach to discovery and development is unproven, and there is no guarantee of developing any commercial products [sec · filed 2023-10-18].
What to watch
- Progress and data from BNC210 clinical trials, especially any Phase 3 initiation or results [sec · filed 2023-10-18].
- Cash runway and any additional financing activities, given the $19.4M cash position as of March 31, 2026 [sec].
- Regulatory developments regarding BNC210 and any FDA interactions [sec_mda · as of 2026-05-15].
- Updates on preclinical programs advancing into clinical development [sec · filed 2023-10-18].
Sources: SEC filings · SEC MD&A · Generated August 14, 2026 · How we verify sources →
Run Neuphoria Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Neuphoria Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
49.8 months
D/E 0.18 · 0% dilution
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
15
Total value held
$5.9M
| Holder | Shares | Value |
|---|---|---|
| lynx1 capital management lp | 875,328 | $3.6M |
| advisorshares investments llc | 155,367 | $632K |
| balyasny asset management l.p. | 142,183 | $579K |
| vanguard capital management llc | 98,516 | $401K |
| geode capital management, llc | 52,007 | $212K |
| vanguard fiduciary trust co | 33,589 | $137K |
| adar1 capital management, llc | 30,000 | $122K |
| citadel advisors llc | 19,331 | $79K |
| boothbay fund management, llc | 14,000 | $57K |
| commonwealth equity services, llc | 11,222 | $46K |
Showing top 10 of 15 institutional holders of Neuphoria Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 0.9%
- Days to cover
- 1.0
- Shares short
- 46,010
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NEUP short interestGovernance
Frequently asked questions
What is the AI investment thesis for Neuphoria Therapeutics Inc.?
Neuphoria Therapeutics Inc. (NEUP) is a clinical-stage biopharmaceutical company focused on developing central nervous system (CNS) therapies, with its lead candidate BNC210 in clinical development and no approved products or revenue to date.
What is Neuphoria Therapeutics Inc.'s lead drug candidate?
Neuphoria Therapeutics Inc.'s most advanced tracked candidate is bnc210 (Phase 3) for Social Anxiety Disorder (SAD).
Who is the CEO of Neuphoria Therapeutics Inc.?
Dr. Spyridon Papapetropoulos M.D., Ph.D. is the chief executive officer of Neuphoria Therapeutics Inc. (NEUP).
Where is Neuphoria Therapeutics Inc. headquartered?
Neuphoria Therapeutics Inc. (NEUP) is headquartered in Burlington, MA, United States.
What therapeutic areas does Neuphoria Therapeutics Inc. focus on?
Neuphoria Therapeutics Inc. develops therapies across Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.